1	LONDON	london	NNP	_	17	npadvmod	17:AM-DIS
2	,	,	,	_	17	punct	_
3	May	may	NNP	_	1	conj	_
4	19	0	CD	_	3	num	_
5	,	,	,	_	17	punct	_
6	2014	0	CD	_	12	num	_
7	/	/	SYM	p2=,	17	punct	_
8	PRNewswire	prnewswire	NNP	p2=NN	12	nn	_
9	/	/	SYM	p2=NNPS	8	punct	_
10	--	--	:	_	8	punct	_
11	 GlaxoSmithKline	 glaxosmithkline	NNP	p2=VB	12	nn	_
12	plc	plc	NNP	p2=NN	17	nsubj	17:A0=PAG
13	(	(	-LRB-	_	12	punct	_
14	GSK.L	gsk.l	NNP	_	12	appos	_
15	)	)	-RRB-	_	12	punct	_
16	today	today	NN	_	17	npadvmod	17:AM-TMP
17	presented	present	VBD	p2=VBN|pb=present.01	0	root	_
18	data	datum	NNS	_	17	dobj	17:A1=PPT
19	at	at	IN	_	17	prep	17:AM-LOC
20	the	the	DT	_	23	det	_
21	American	american	NNP	p2=JJ	23	nn	_
22	Thoracic	thoracic	NNP	_	23	nn	_
23	Society	society	NNP	_	19	pobj	_
24	(	(	-LRB-	_	23	punct	_
25	ATS	ats	NNP	p2=NNPS	23	appos	_
26	)	)	-RRB-	_	23	punct	_
27	from	from	IN	_	17	prep	17:A3
28	a	a	DT	_	33	det	_
29	late	late	JJ	_	31	hmod	_
30	-	-	HYPH	_	31	hyph	_
31	stage	stage	NN	_	33	nn	_
32	clinical	clinical	JJ	_	33	amod	_
33	study	study	NN	_	27	pobj	_
34	.	.	.	_	17	punct	_

1	In	in	IN	_	68	prep	68:AM-LOC
2	this	this	DT	_	3	det	_
3	study	study	NN	_	1	pobj	_
4	the	the	DT	_	5	det	_
5	safety	safety	NN	_	59	nn	_
6	and	and	CC	_	5	cc	_
7	efficacy	efficacy	NN	_	5	conj	_
8	of	of	IN	_	5	prep	_
9	the	the	DT	_	10	det	_
10	addition	addition	NN	_	8	pobj	_
11	of	of	IN	_	10	prep	_
12	a	a	DT	_	17	det	_
13	long	long	RB	_	15	hmod	_
14	-	-	HYPH	_	15	hyph	_
15	acting	act	VBG	_	17	amod	_
16	muscarinic	muscarinic	NN	p2=JJ	17	nn	_
17	antagonist	antagonist	NN	p2=JJ	11	pobj	20:A1=PPT
18	(	(	-LRB-	_	20	punct	_
19	also	also	RB	_	20	advmod	20:AM-DIS
20	known	know	VBN	pb=know.01	17	partmod	_
21	as	as	IN	_	20	prep	20:A2=PRD
22	an	an	DT	_	23	det	_
23	anticholinergic	anticholinergic	JJ	p2=NN	21	pobj	_
24	)	)	-RRB-	_	20	punct	_
25	,	,	,	_	68	punct	_
26	umeclidinium	umeclidinium	NN	p2=UH	28	nn	_
27	'	'	``	p2=POS	28	punct	_
28	UMEC	umec	NNP	_	68	nsubjpass	68:A1=PPT
29	'	'	''	_	28	punct	_
30	62.5mcg	0mcg	''	p2=NN	28	punct	_
31	(	(	-LRB-	_	28	punct	_
32	Incruse™	incruse™	NNP	p2=``	33	nn	_
33	Ellipta®	ellipta®	NNP	_	28	appos	_
34	)	)	-RRB-	_	28	punct	_
35	and	and	CC	_	28	cc	_
36	UMEC	umec	NNP	_	37	nn	_
37	125mcg	125mcg	NNP	p2=CD	28	conj	_
38	,	,	,	_	68	punct	_
39	to	to	IN	_	68	prep	_
40	the	the	DT	_	42	det	_
41	inhaled	inhale	VBN	p2=JJ|pb=inhale.01	42	amod	_
42	corticosteroid	corticosteroid	JJ	p2=NN	39	pobj	41:A1=PPT
43	and	and	CC	_	42	cc	_
44	long	long	RB	p2=JJ	46	hmod	_
45	-	-	HYPH	_	46	hyph	_
46	acting	act	VBG	_	50	amod	_
47	beta2	beta0	NN	p2=IN	48	nn	_
48	agonist	agonist	NN	p2=IN	50	amod	_
49	combination	combination	NN	_	50	nn	_
50	medicine	medicine	NN	_	42	conj	_
51	,	,	,	_	50	punct	_
52	fluticasone	fluticasone	NN	p2=JJ	53	nn	_
53	proprionate	proprionate	NN	p2=VB	50	conj	_
54	and	and	CC	_	53	cc	_
55	salmeterol	salmeterol	NN	p2=VBD	53	conj	_
56	'	'	''	p2=POS	59	punct	_
57	FSC	fsc	NNP	p2=RB	59	nn	_
58	250/50	0	CD	_	59	num	_
59	mcg	mcg	NN	p2=RBS	53	conj	_
60	'	'	''	p2=POS	59	punct	_
61	(	(	-LRB-	_	59	punct	_
62	Advair	advair	NNP	p2=FW	64	nn	_
63	®	®	NNP	p2=:	64	nn	_
64	Diskus®	diskus®	NNP	_	59	appos	_
65	)	)	-RRB-	_	59	punct	_
66	,	,	,	_	68	punct	_
67	was	be	VBD	_	68	auxpass	_
68	evaluated	evaluate	VBN	pb=evaluate.01	0	root	_
69	in	in	IN	_	68	prep	68:AM-LOC
70	chronic	chronic	JJ	_	73	amod	_
71	obstructive	obstructive	JJ	p2=NN	73	amod	_
72	pulmonary	pulmonary	JJ	_	73	amod	_
73	disease	disease	NN	_	69	pobj	_
74	(	(	-LRB-	_	77	punct	_
75	COPD	copd	NNP	p2=NN	77	nn	_
76	)	)	-RRB-	_	77	punct	_
77	patients	patient	NNS	p2=VBZ	73	appos	_
78	over	over	IN	_	79	quantmod	_
79	12	0	CD	_	80	num	_
80	weeks	week	NNS	_	68	npadvmod	_
81	.	.	.	_	68	punct	_

1	The	the	DT	_	2	det	_
2	study	study	NN	_	3	nsubj	3:A0=CAU
3	showed	show	VBD	pb=show.01	0	root	_
4	that	that	IN	_	31	complm	_
5	,	,	,	_	31	punct	_
6	for	for	IN	_	31	prep	_
7	the	the	DT	_	9	det	_
8	primary	primary	JJ	_	9	amod	_
9	endpoint	endpoint	NN	_	6	pobj	_
10	of	of	IN	_	9	prep	_
11	trough	trough	NN	_	10	pobj	_
12	FEV1	fev1	NNP	p2=CD	44	nsubj	44:A1=PPT
13	at	at	IN	_	12	prep	_
14	Day	day	NNP	_	13	pobj	_
15	85	0	CD	p2=NNP	14	num	_
16	,	,	,	_	31	punct	_
17	the	the	DT	_	18	det	_
18	addition	addition	NN	_	31	nsubj	31:A1=PPT
19	of	of	IN	_	18	prep	_
20	UMEC	umec	NNP	_	19	pobj	_
21	 	 	''	p2=NNP	31	punct	_
22	(	(	-LRB-	_	31	punct	_
23	at	at	IN	_	31	prep	_
24	either	either	DT	p2=CC	25	det	_
25	dose	dose	NN	_	23	pobj	_
26	)	)	-RRB-	_	31	punct	_
27	to	to	IN	p2=TO	18	prep	_
28	FSC	fsc	NNP	p2=$	30	nn	_
29	250/50	0	CD	_	30	num	_
30	mcg	mcg	NN	p2=NNP	27	pobj	_
31	resulted	result	VBD	p2=VBN|pb=result.01	3	ccomp	3:A1=PPT
32	in	in	IN	_	31	prep	31:A2=LOC
33	a	a	DT	_	36	det	_
34	statistically	statistically	RB	_	35	advmod	_
35	significant	significant	JJ	_	36	amod	_
36	improvement	improvement	NN	_	32	pobj	_
37	in	in	IN	_	36	prep	_
38	lung	lung	NN	_	39	nn	_
39	function	function	NN	_	37	pobj	_
40	when	when	WRB	_	41	advmod	41:R-AM-TMP
41	compared	compare	VBN	pb=compare.01	31	advcl	31:AM-TMP
42	with	with	IN	_	41	prep	41:A2=PPT
43	placebo	placebo	NN	_	42	pobj	_
44	added	add	VBN	p2=VBD|pb=add.02	43	partmod	_
45	on	on	IN	p2=RP	44	prep	44:A2=PPT
46	to	to	IN	p2=TO	45	prep	_
47	FSC	fsc	NNP	_	49	nn	_
48	250/50	0	CD	p2=NNP	47	num	_
49	mcg	mcg	NN	p2=NNS	46	pobj	_
50	,	,	,	_	49	punct	_
51	in	in	IN	_	44	prep	44:AM-TMP
52	patients	patient	NNS	_	51	pobj	_
53	with	with	IN	_	52	prep	_
54	COPD	copd	NNP	p2=NN	53	pobj	_
55	.	.	.	_	3	punct	_

1	The	the	DT	_	2	det	_
2	addition	addition	NN	_	14	nsubj	14:A0
3	of	of	IN	_	2	prep	_
4	UMEC	umec	NNP	_	3	pobj	_
5	(	(	-LRB-	_	6	punct	_
6	at	at	IN	_	2	prep	_
7	either	either	DT	p2=CC	8	det	_
8	dose	dose	NN	_	6	pobj	_
9	)	)	-RRB-	_	6	punct	_
10	to	to	IN	p2=TO	2	prep	_
11	FSC	fsc	NNP	_	12	nn	_
12	250/50mcg	250/50mcg	NNP	p2=CD	10	pobj	_
13	also	also	RB	_	14	advmod	14:AM-DIS
14	demonstrated	demonstrate	VBD	pb=demonstrate.01	0	root	_
15	statistically	statistically	RB	_	16	advmod	_
16	significant	significant	JJ	_	17	amod	_
17	improvements	improvement	NNS	_	26	nsubj	26:A0=PAG
18	in	in	IN	_	17	prep	_
19	secondary	secondary	JJ	_	20	amod	_
20	efficacy	efficacy	NN	p2=JJ	21	nn	_
21	endpoints	endpoint	NNS	p2=NN	18	pobj	_
22	of	of	IN	_	21	prep	_
23	0-6	0	CD	_	24	num	_
24	hour	hour	NN	_	22	pobj	_
25	weighted	weight	VBN	p2=VBD|pb=weight.01	35	amod	_
26	mean	mean	VBP	p2=JJ|pb=mean.01	14	ccomp	14:A1=PPT
27	FEV1	fev1	NNP	p2=CD	32	nsubj	32:A0=PAG
28	at	at	IN	_	27	prep	_
29	Day	day	NNP	_	28	pobj	_
30	84	0	CD	p2=NNP	29	num	_
31	and	and	CC	_	26	cc	_
32	mean	mean	VB	p2=JJ|pb=mean.01	26	conj	_
33	number	number	NN	_	32	dobj	32:A1=PPT
34	of	of	IN	_	33	prep	_
35	puffs	puff	NNS	_	34	pobj	25:A1=PPT
36	of	of	IN	_	35	prep	_
37	rescue	rescue	NN	_	38	nn	_
38	medicine	medicine	NN	_	36	pobj	_
39	per	per	IN	_	38	prep	_
40	day	day	NN	_	39	pobj	_
41	(	(	-LRB-	_	38	punct	_
42	weeks	week	NNS	_	38	appos	_
43	1-12	0	CD	p2=LS	42	num	_
44	)	)	-RRB-	_	14	punct	_
45	compared	compare	VBN	p2=VBD	25	prep	_
46	with	with	IN	_	45	prep	_
47	the	the	DT	_	48	det	_
48	addition	addition	NN	_	46	pobj	_
49	of	of	IN	_	48	prep	_
50	placebo	placebo	NN	_	49	pobj	_
51	to	to	IN	p2=TO	48	prep	_
52	FSC	fsc	NNP	_	51	pobj	_
53	250/50	0	CD	_	54	num	_
54	mcg	mcg	NN	p2=RB	52	appos	_
55	.	.	.	_	14	punct	_

1	Darrell	darrell	NNP	_	2	nn	_
2	Baker	baker	NNP	_	13	nsubj	13:A0
3	,	,	,	_	2	punct	_
4	SVP	svp	NNP	_	2	conj	_
5	and	and	CC	_	4	cc	_
6	Head	head	NNP	_	4	conj	_
7	,	,	,	_	4	punct	_
8	Global	global	NNP	p2=JJ	10	nn	_
9	Respiratory	respiratory	NNP	_	10	nn	_
10	Franchise	franchise	NNP	_	4	conj	_
11	,	,	,	_	10	punct	_
12	GSK	gsk	NNP	_	10	conj	_
13	said	say	VBD	pb=say.01	0	root	_
14	:	:	:	p2=``	13	punct	_
15	 	 	,	p2=:	13	punct	_
16	"	"	``	_	13	punct	_
17	We	we	PRP	_	18	nsubj	18:A1=PPT;21:A1=PPT
18	are	be	VBP	pb=be.01	13	ccomp	13:A1=PPT
19	pleased	pleased	JJ	_	18	acomp	18:A2=PRD
20	to	to	TO	_	21	aux	_
21	be	be	VB	pb=be.01	19	xcomp	_
22	able	able	JJ	_	21	acomp	21:A2=PRD
23	to	to	TO	_	24	aux	_
24	share	share	VB	pb=share.01	22	xcomp	_
25	these	these	DT	_	26	det	_
26	results	result	NNS	_	24	dobj	24:A1=PPT
27	with	with	IN	_	24	prep	24:A2=COM
28	physicians	physician	NNS	_	27	pobj	_
29	from	from	IN	_	28	prep	_
30	across	across	IN	_	29	prep	_
31	the	the	DT	_	32	det	_
32	world	world	NN	_	30	pobj	_
33	at	at	IN	_	24	prep	_
34	this	this	DT	_	36	det	_
35	international	international	JJ	_	36	amod	_
36	congress	congress	NN	_	33	pobj	_
37	.	.	.	_	13	punct	_

1	The	the	DT	_	2	det	_
2	ATS	ats	NNP	p2=NNPS	3	nsubj	3:A0=PAG
3	provides	provide	VBZ	pb=provide.01	0	root	_
4	a	a	DT	_	5	det	_
5	forum	forum	NN	_	3	dobj	3:A1=PPT
6	for	for	IN	_	5	prep	_
7	scientific	scientific	JJ	_	8	amod	_
8	discussion	discussion	NN	_	6	pobj	_
9	and	and	CC	_	3	cc	_
10	we	we	PRP	_	11	nsubj	11:A0=PAG;14:A0=PAG
11	look	look	VBP	pb=look.03	3	conj	_
12	forward	forward	RB	_	11	advmod	11:C-V
13	to	to	IN	p2=TO	12	prep	_
14	understanding	understand	VBG	pb=understand.01	13	pcomp	_
15	the	the	DT	_	19	det	_
16	scientific	scientific	JJ	p2=NN	19	amod	_
17	and	and	CC	_	16	cc	_
18	healthcare	healthcare	NN	p2=JJ	16	conj	_
19	communities	community	NNS	_	21	poss	_
20	'	'	POS	_	19	possessive	_
21	perspectives	perspective	NNS	_	14	dobj	14:A1=PPT
22	of	of	IN	_	21	prep	_
23	these	these	DT	_	25	det	_
24	new	new	JJ	_	25	amod	_
25	data	datum	NNS	p2=NN	22	pobj	_
26	.	.	.	_	11	punct	_
27	"	"	''	_	11	punct	_

1	There	there	EX	_	2	expl	_
2	were	be	VBD	pb=be.02	0	root	_
3	no	no	DT	_	5	det	_
4	notable	notable	JJ	_	5	amod	_
5	differences	difference	NNS	_	2	attr	2:A1=PPT
6	between	between	IN	_	5	prep	_
7	UMEC	umec	NNP	_	6	pobj	_
8	(	(	-LRB-	_	7	punct	_
9	at	at	IN	_	5	prep	_
10	either	either	DT	p2=CC	11	det	_
11	dose	dose	NN	_	9	pobj	_
12	)	)	-RRB-	_	2	punct	_
13	added	add	VBD	p2=VBN|pb=add.01	2	advcl	_
14	to	to	IN	p2=TO	13	prep	13:AM-NEG
15	FSC	fsc	NNP	_	14	pobj	_
16	250/50	0	CD	_	15	num	_
17	mcg	mcg	NN	p2=NNS	20	nsubj	20:A0=PAG
18	and	and	CC	_	17	cc	_
19	placebo	placebo	NN	_	17	conj	_
20	added	add	VBD	p2=VBN|pb=add.01	13	ccomp	13:A1=PPT
21	to	to	IN	p2=TO	20	prep	20:AM-DIR
22	FSC	fsc	NNP	_	21	pobj	_
23	250/50	0	CD	_	22	num	_
24	mcg	mcg	NN	p2=RB	20	dobj	20:A1=PPT
25	in	in	IN	_	24	prep	_
26	incidence	incidence	NN	_	27	nn	_
27	rates	rate	NNS	_	25	pobj	_
28	of	of	IN	_	27	prep	_
29	on	on	IN	_	31	hmod	_
30	-	-	HYPH	_	31	hyph	_
31	treatment	treatment	NN	_	33	nn	_
32	adverse	adverse	JJ	_	33	amod	_
33	events	event	NNS	_	28	pobj	_
34	or	or	CC	_	25	cc	_
35	in	in	IN	_	25	conj	_
36	changes	change	NNS	_	35	pobj	_
37	from	from	IN	_	36	prep	_
38	baseline	baseline	NN	_	37	pobj	_
39	in	in	IN	_	36	prep	_
40	vital	vital	JJ	_	41	amod	_
41	signs	sign	NNS	_	39	pobj	_
42	.	.	.	_	2	punct	_

1	This	this	DT	_	2	nsubj	2:A1=PPT
2	was	be	VBD	pb=be.01	0	root	_
3	a	a	DT	_	17	det	_
4	12	0	CD	_	6	hmod	_
5	-	-	HYPH	_	6	hyph	_
6	week	week	NN	_	17	nn	_
7	,	,	,	_	17	punct	_
8	randomised	randomize	VBD	p2=VBN|pb=randomize.01	17	amod	_
9	,	,	,	_	17	punct	_
10	double	double	JJ	p2=RB	12	hmod	_
11	-	-	HYPH	_	12	hyph	_
12	blind	blind	JJ	_	17	amod	_
13	,	,	,	_	17	punct	_
14	parallel	parallel	JJ	p2=NN	16	hmod	_
15	-	-	HYPH	_	16	hyph	_
16	group	group	NN	_	17	nn	_
17	study	study	NN	_	2	attr	8:A1=PPT;2:A2=PRD
18	.	.	.	_	2	punct	_

1	Approximately	approximately	RB	_	2	advmod	_
2	600	0	CD	_	4	num	_
3	eligible	eligible	JJ	_	4	amod	_
4	patients	patient	NNS	_	6	nsubjpass	6:A1=PPT
5	were	be	VBD	_	6	auxpass	_
6	randomised	randomize	VBN	p2=JJ|pb=randomize.01	25	ccomp	25:A1=PPT
7	1:1	0	CD	_	6	npadvmod	_
8	:	:	SYM	p2=:	9	punct	_
9	1	0	CD	_	7	prep	_
10	to	to	IN	p2=TO	6	prep	6:A2=GOL
11	once	once	RB	_	13	hmod	_
12	-	-	HYPH	_	13	hyph	_
13	daily	daily	RB	p2=JJ	16	amod	_
14	UMEC	umec	NNP	p2=$	16	nn	_
15	62.5	0	CD	_	16	num	_
16	mcg	mcg	NN	p2=RB	10	pobj	_
17	,	,	,	_	16	punct	_
18	UMEC	umec	NNP	_	20	nn	_
19	125	0	CD	_	20	num	_
20	mcg	mcg	NN	p2=NNP	16	appos	_
21	,	,	,	_	20	punct	_
22	or	or	CC	_	20	cc	_
23	placebo	placebo	NN	_	20	conj	_
24	,	,	,	_	25	punct	_
25	added	add	VBD	p2=VBN|pb=add.01	0	root	_
26	to	to	IN	p2=TO	25	prep	25:A0=PAG
27	FSC	fsc	NNP	_	26	pobj	_
28	(	(	-LRB-	_	30	punct	_
29	250/50	0	CD	_	30	num	_
30	mcg	mcg	NN	p2=NNS	27	parataxis	_
31	twice	twice	RB	p2=PDT	32	advmod	_
32	daily	daily	RB	_	25	advmod	25:AM-TMP
33	)	)	-RRB-	_	25	punct	_
34	.	.	.	_	25	punct	_

1	UMEC	umec	NNP	p2=NN	5	nsubjpass	5:A1=PPT
2	and	and	CC	_	1	cc	_
3	placebo	placebo	NN	_	1	conj	_
4	were	be	VBD	_	5	auxpass	_
5	administered	administer	VBN	pb=administer.01	0	root	_
6	via	via	IN	_	5	prep	5:AM-MNR
7	Ellipta	ellipta	NNP	p2=FW	10	nn	_
8	dry	dry	JJ	_	9	amod	_
9	powder	powder	NN	_	10	nn	_
10	inhaler	inhaler	NN	p2=RBR	6	pobj	_
11	and	and	CC	_	10	cc	_
12	FSC	fsc	NNP	p2=NN	10	conj	_
13	via	via	IN	_	5	prep	5:AM-MNR
14	Diskus®	diskus®	NNP	p2=NNPS	15	nn	_
15	inhaler	inhaler	NN	p2=NNP	13	pobj	_
16	.	.	.	_	5	punct	_

1	The	the	DT	_	3	det	_
2	primary	primary	JJ	p2=NN	3	amod	_
3	endpoint	endpoint	NN	p2=NNP	4	nsubj	4:A1=PPT
4	was	be	VBD	pb=be.01	0	root	_
5	trough	trough	NN	p2=RB	6	npadvmod	6:A0=PAG
6	forced	force	VBN	p2=VBD|pb=force.01	4	ccomp	4:A2=PRD
7	expiratory	expiratory	NN	p2=JJ	8	nn	_
8	volume	volume	NN	_	6	dobj	6:A1=PPT
9	in	in	IN	_	6	prep	6:AM-TMP
10	one	#crd#	CD	_	11	num	_
11	second	#ord#	JJ	p2=NN	9	pobj	_
12	(	(	-LRB-	_	13	punct	_
13	FEV1	fev1	NNP	p2=NN	11	appos	_
14	)	)	-RRB-	_	13	punct	_
15	on	on	IN	_	11	prep	_
16	Day	day	NNP	p2=NN	15	pobj	_
17	85	0	CD	_	16	num	_
18	.	.	.	_	4	punct	_

1	Secondary	secondary	JJ	_	2	amod	_
2	endpoints	endpoint	NNS	_	3	nsubj	3:A1=PPT
3	were	be	VBD	pb=be.01	0	root	_
4	0-6	0	CD	_	6	hmod	_
5	-	-	HYPH	_	6	hyph	_
6	hour	hour	NN	_	7	nn	_
7	post-dose	post-dose	NN	p2=JJ	3	attr	3:A2=PRD
8	weighted	weight	VBN	p2=VBD|pb=weight.01	9	amod	_
9	mean	mean	NN	p2=VBP	13	nn	8:A1=PPT
10	(	(	-LRB-	_	13	punct	_
11	WM	wm	NNP	p2=NN	13	nn	_
12	)	)	-RRB-	_	13	punct	_
13	FEV1	fev1	NNP	p2=NN	3	attr	_
14	on	on	IN	_	13	prep	_
15	Day	day	NNP	_	14	pobj	_
16	84	0	CD	_	15	num	_
17	and	and	CC	_	9	cc	_
18	rescue	rescue	VB	pb=rescue.01	3	conj	_
19	albuterol	albuterol	NN	p2=NNS	20	nn	_
20	use	use	NN	p2=VBP	18	dobj	18:A1=PPT
21	(	(	-LRB-	_	22	punct	_
22	percentage	percentage	NN	_	20	appos	_
23	of	of	IN	_	22	prep	_
24	rescue	rescue	NN	_	26	hmod	_
25	-	-	HYPH	_	26	hyph	_
26	free	free	JJ	_	27	amod	_
27	days	day	NNS	_	23	pobj	_
28	and	and	CC	_	27	cc	_
29	puffs	puff	NNS	_	27	conj	_
30	/	/	SYM	p2=,	31	punct	_
31	day	day	NN	_	22	appos	_
32	)	)	-RRB-	_	22	punct	_
33	.	.	.	_	3	punct	_

1	Safety	safety	NN	p2=NNP	2	nn	_
2	endpoints	endpoint	NNS	p2=VBZ	3	nsubj	3:A2=GOL
3	included	include	VBD	pb=include.01	0	root	_
4	the	the	DT	_	5	det	_
5	incidence	incidence	NN	_	3	dobj	3:A1=PPT
6	of	of	IN	_	5	prep	_
7	on	on	IN	p2=RB	9	hmod	_
8	-	-	HYPH	_	9	hyph	_
9	treatment	treatment	NN	_	11	nn	_
10	adverse	adverse	JJ	_	11	amod	_
11	events	event	NNS	_	6	pobj	_
12	(	(	-LRB-	_	13	punct	_
13	AEs	aes	NNP	_	11	appos	_
14	)	)	-RRB-	_	13	punct	_
15	,	,	,	_	11	punct	_
16	vital	vital	JJ	_	17	amod	_
17	signs	sign	NNS	_	11	conj	_
18	and	and	CC	_	17	cc	_
19	COPD	copd	NNP	p2=VBN	20	nn	_
20	exacerbations	exacerbation	NNS	_	17	conj	_
21	.	.	.	_	3	punct	_

1	Umeclidinium	umeclidinium	NN	p2=NNP	4	nsubjpass	4:A1=PPT
2	is	be	VBZ	_	4	auxpass	_
3	only	only	RB	_	4	advmod	4:AM-ADV
4	approved	approve	VBN	pb=approve.01	0	root	_
5	for	for	IN	_	4	prep	4:A2=PRD
6	use	use	NN	_	5	pobj	_
7	in	in	IN	_	6	prep	_
8	the	the	DT	_	9	det	_
9	US	us	NNP	_	7	pobj	_
10	,	,	,	_	9	punct	_
11	Canada	canada	NNP	_	9	conj	_
12	and	and	CC	_	11	cc	_
13	Europe	europe	NNP	_	11	conj	_
14	.	.	.	_	4	punct	_

1	It	it	PRP	_	4	nsubjpass	4:A1=PPT
2	is	be	VBZ	_	4	auxpass	_
3	not	not	RB	_	4	neg	4:AM-NEG
4	approved	approve	VBN	pb=approve.01	0	root	_
5	anywhere	anywhere	RB	_	6	advmod	_
6	else	else	RB	_	4	advmod	4:AM-LOC
7	in	in	IN	_	4	prep	4:AM-LOC
8	the	the	DT	_	9	det	_
9	world	world	NN	_	7	pobj	_
10	.	.	.	_	4	punct	_

1	Umeclidinium	umeclidinium	UH	p2=NN	3	intj	3:AM-DIS
2	125mcg	0mcg	NN	p2=LS	3	nsubj	3:A1=PPT
3	is	be	VBZ	pb=be.01	0	root	_
4	not	not	RB	_	3	neg	3:AM-NEG
5	an	an	DT	_	7	det	_
6	approved	approve	VBN	p2=JJ|pb=approve.01	7	amod	_
7	dose	dose	NN	_	3	attr	6:A1=PPT;3:A2=PRD
8	anywhere	anywhere	RB	_	3	advmod	_
9	in	in	IN	_	8	prep	_
10	the	the	DT	_	11	det	_
11	world	world	NN	_	9	pobj	_
12	.	.	.	_	3	punct	_

1	Seretide	seretide	NNP	p2=NN	3	nsubj	3:A1=PPT
2	500/50	0	CD	_	1	num	_
3	is	be	VBZ	pb=be.01	0	root	_
4	the	the	DT	_	5	det	_
5	licensed dose	licensed dose	NN	p2=NNP	3	attr	3:A2=PRD
6	for	for	IN	_	5	prep	_
7	treatment	treatment	NN	_	6	pobj	_
8	of	of	IN	_	7	prep	_
9	COPD	copd	NNP	p2=NN	12	nn	_
10	in the	in the	NNP	p2=POS	12	nn	_
11	European	european	NNP	_	12	nn	_
12	Union	union	NNP	_	8	pobj	_
13	.	.	.	_	3	punct	_

1	Incruse	incruse	NNP	p2=IN	2	nn	_
2	Ellipta	ellipta	NNP	_	3	nsubj	3:A1=PPT
3	is	be	VBZ	pb=be.01	0	root	_
4	an	an	DT	_	5	det	_
5	anticholinergic	anticholinergic	JJ	p2=NN	3	attr	6:A1=PPT;3:A2=PRD
6	approved	approve	VBN	p2=NN|pb=approve.01	5	partmod	_
7	in	in	IN	_	6	prep	6:AM-LOC
8	the	the	DT	_	9	det	_
9	US	us	NNP	_	7	pobj	_
10	for	for	IN	_	6	prep	6:A2=PRD
11	the	the	DT	_	14	det	_
12	long	long	JJ	_	14	hmod	_
13	-	-	HYPH	_	14	hyph	_
14	term	term	NN	_	10	pobj	_
15	once	once	RB	_	17	hmod	_
16	-	-	HYPH	p2=:	17	hyph	_
17	daily	daily	JJ	p2=RB	19	amod	_
18	maintenance	maintenance	NN	_	19	nn	_
19	treatment	treatment	NN	_	14	appos	_
20	of	of	IN	_	19	prep	_
21	airflow	airflow	NN	p2=JJ	22	nn	_
22	obstruction	obstruction	NN	_	20	pobj	_
23	in	in	IN	_	19	prep	_
24	patients	patient	NNS	_	23	pobj	_
25	with	with	IN	_	24	prep	_
26	chronic	chronic	JJ	_	29	amod	_
27	obstructive	obstructive	JJ	p2=NN	29	amod	_
28	pulmonary	pulmonary	JJ	_	29	amod	_
29	disease	disease	NN	_	25	pobj	_
30	(	(	-LRB-	_	31	punct	_
31	COPD	copd	NNP	p2=NN	29	appos	_
32	)	)	-RRB-	_	31	punct	_
33	,	,	,	_	29	punct	_
34	including	include	VBG	_	29	prep	_
35	chronic	chronic	JJ	_	36	amod	_
36	bronchitis	bronchitis	NN	p2=NNS	34	pobj	_
37	and	and	CC	_	36	cc	_
38	/	/	SYM	_	36	punct	_
39	or	or	CC	_	36	cc	_
40	emphysema	emphysema	NN	p2=NNP	36	conj	_
41	.	.	.	_	3	punct	_

1	Incruse	incruse	NNP	p2=JJ	2	nn	_
2	Ellipta	ellipta	NNP	_	4	nsubjpass	4:A1=PPT
3	is	be	VBZ	_	4	auxpass	_
4	approved	approve	VBN	pb=approve.01	0	root	_
5	in	in	IN	_	4	prep	4:AM-LOC
6	the	the	DT	_	7	det	_
7	EU	eu	NNP	_	5	pobj	_
8	as	as	IN	_	4	prep	4:A2=PRD
9	a	a	DT	_	16	det	_
10	once	once	RB	_	12	hmod	_
11	-	-	HYPH	_	12	hyph	_
12	daily	daily	RB	p2=JJ	16	amod	_
13	,	,	,	_	16	punct	_
14	maintenance	maintenance	NN	_	15	nn	_
15	bronchodilator	bronchodilator	NN	p2=XX	16	nn	_
16	treatment	treatment	NN	_	8	pobj	_
17	to	to	TO	_	18	aux	_
18	relieve	relieve	VB	pb=relieve.01	16	infmod	_
19	symptoms	symptom	NNS	_	18	dobj	18:A1=DIR
20	in	in	IN	_	18	prep	_
21	adult	adult	NN	p2=JJ	22	nn	_
22	patients	patient	NNS	_	20	pobj	_
23	with	with	IN	_	22	prep	_
24	chronic	chronic	JJ	_	27	amod	_
25	obstructive	obstructive	JJ	p2=NN	27	amod	_
26	pulmonary	pulmonary	JJ	_	27	amod	_
27	disease	disease	NN	_	23	pobj	_
28	(	(	-LRB-	_	27	punct	_
29	COPD	copd	NNP	p2=NN	27	appos	_
30	)	)	-RRB-	_	27	punct	_
31	.	.	.	_	4	punct	_

1	Incruse	incruse	NNP	p2=NN	2	nsubj	2:A0
2	contains	contain	VBZ	pb=contain.01	0	root	_
3	62.5	0	CD	_	5	num	_
4	mcg	mcg	NN	p2=NNS	5	nn	_
5	umeclidinium	umeclidinium	NN	p2=NNS	2	dobj	2:A1;6:A1=PPT
6	delivered	deliver	VBN	pb=deliver.01	5	partmod	_
7	by	by	IN	_	6	agent	6:A0=PAG
8	the	the	DT	_	10	det	_
9	Ellipta	ellipta	NNP	p2=NNPS	10	nn	_
10	inhaler	inhaler	NN	p2=NNP	7	pobj	_
11	.	.	.	_	2	punct	_

1	Full	full	JJ	_	4	amod	_
2	US	us	NNP	_	4	nn	_
3	Prescribing	prescribing	NNP	p2=VBG	4	nn	_
4	Information	information	NNP	p2=NN	9	nsubj	9:A1=PPT
5	including	include	VBG	_	4	prep	_
6	Patient	patient	NNP	p2=NN	8	nn	_
7	Information	information	NNP	p2=NN	8	nn	_
8	Leaflet	leaflet	NNP	_	5	pobj	_
9	are	be	VBP	pb=be.01	0	root	_
10	available	available	JJ	_	9	acomp	9:A2=PRD
11	at	at	IN	_	9	prep	9:AM-LOC
12	:	:	:	_	11	punct	_
13	us.gsk.com	#url#	ADD	_	11	pobj	_
14	.	.	.	_	9	punct	_

1	The	the	DT	_	5	det	_
2	following	follow	VBG	pb=follow.04	5	amod	_
3	Important	important	NNP	p2=JJ	5	nn	_
4	Safety	safety	NNP	_	5	nn	_
5	Information	information	NNP	_	7	nsubjpass	2:A1=PPT;7:A1=PPT
6	is	be	VBZ	_	7	auxpass	_
7	based	base	VBN	pb=base.02	0	root	_
8	on	on	IN	_	7	prep	7:A2=DIR
9	the	the	DT	_	11	det	_
10	Highlights	highlight	NNS	p2=NNP	11	nn	_
11	section	section	NN	_	8	pobj	_
12	of	of	IN	_	11	prep	_
13	the	the	DT	_	15	det	_
14	Prescribing	prescribing	NNP	_	15	nn	_
15	Information	information	NNP	p2=NN	12	pobj	_
16	for	for	IN	_	11	prep	_
17	Incruse	incruse	NNP	_	18	nn	_
18	Ellipta	ellipta	NNP	_	16	pobj	_
19	.	.	.	_	7	punct	_

1	 	 	TO	p2=:	3	aux	_
2	Please	please	UH	_	3	intj	3:AM-DIS
3	consult	consult	VB	pb=consult.01	0	root	_
4	the	the	DT	_	7	det	_
5	full	full	JJ	_	7	amod	_
6	Prescribing	prescribing	NNP	_	7	nn	_
7	Information	information	NNP	p2=NN	3	dobj	3:A1
8	for	for	IN	_	3	prep	3:AM-PRP
9	all	all	PDT	_	13	predet	_
10	the	the	DT	_	13	det	_
11	labeled	label	VBN	p2=JJ|pb=label.01	13	amod	_
12	safety	safety	NN	_	13	nn	_
13	information	information	NN	_	8	pobj	11:A1
14	for	for	IN	_	13	prep	_
15	Incruse	incruse	NNP	p2=NN	16	nn	_
16	Ellipta	ellipta	NNP	_	14	pobj	_
17	.	.	.	_	3	punct	_

1	Incruse	incruse	NNP	p2=NN	2	nn	_
2	Ellipta	ellipta	NNP	_	4	nsubjpass	4:A1
3	is	be	VBZ	_	4	auxpass	_
4	contraindicated	contraindicate	VBN	p2=JJ|pb=contraindicate.01	0	root	_
5	in	in	IN	_	4	prep	4:AM-LOC
6	patients	patient	NNS	_	5	pobj	_
7	with	with	IN	_	6	prep	_
8	severe	severe	JJ	_	9	amod	_
9	hypersensitivity	hypersensitivity	NN	_	7	pobj	_
10	to	to	IN	p2=TO	9	prep	_
11	milk	milk	NN	_	12	nn	_
12	proteins	protein	NNS	_	10	pobj	_
13	or	or	CC	_	4	cc	_
14	who	who	WP	_	16	nsubj	16:R-A0
15	have	have	VBP	_	16	aux	_
16	demonstrated	demonstrate	VBN	pb=demonstrate.01	4	conj	_
17	hypersensitivity	hypersensitivity	NN	p2=RP	16	dobj	16:A1=PPT
18	to	to	IN	_	16	prep	16:A2=GOL
19	either	either	CC	p2=DT	20	preconj	_
20	umeclidinium	umeclidinium	VB	_	18	pobj	_
21	,	,	,	_	16	punct	_
22	or	or	CC	_	16	cc	_
23	any	any	DT	_	16	conj	_
24	of	of	IN	_	23	prep	_
25	the	the	DT	_	27	det	_
26	other	other	JJ	_	27	amod	_
27	ingredients	ingredient	NNS	_	24	pobj	_
28	.	.	.	_	4	punct	_

1	Incruse	incruse	NNP	p2=IN	2	nn	_
2	Ellipta	ellipta	NNP	_	6	nsubjpass	6:A1=PPT
3	should	should	MD	_	6	aux	6:AM-MOD
4	not	not	RB	_	6	neg	6:AM-NEG
5	be	be	VB	_	6	auxpass	_
6	initiated	initiate	VBN	pb=initiate.01	0	root	_
7	in	in	IN	_	6	prep	6:AM-LOC
8	patients	patient	NNS	_	7	pobj	_
9	during	during	IN	_	6	prep	6:AM-TMP
10	rapidly	rapidly	RB	_	11	advmod	_
11	deteriorating	deteriorate	VBG	_	9	pobj	_
12	or	or	CC	_	11	cc	_
13	potentially	potentially	RB	_	16	advmod	_
14	life	life	NN	_	16	hmod	_
15	-	-	HYPH	_	16	hyph	_
16	threatening	threaten	VBG	_	11	conj	_
17	episodes	episode	NNS	_	16	dobj	_
18	of	of	IN	_	17	prep	_
19	COPD	copd	NNP	p2=NN	18	pobj	_
20	,	,	,	_	16	punct	_
21	or	or	CC	_	16	cc	_
22	as	as	IN	_	14	prep	_
23	rescue	rescue	NN	_	24	nn	_
24	therapy	therapy	NN	_	22	pobj	_
25	for	for	IN	_	24	prep	_
26	the	the	DT	_	27	det	_
27	treatment	treatment	NN	_	25	pobj	_
28	of	of	IN	_	27	prep	_
29	acute	acute	JJ	_	30	amod	_
30	episodes	episode	NNS	_	28	pobj	37:A1=PPT
31	of	of	IN	_	30	prep	_
32	bronchospasm	bronchospasm	NN	_	31	pobj	_
33	,	,	,	_	32	punct	_
34	which	which	WDT	_	37	nsubjpass	37:R-A1
35	should	should	MD	_	37	aux	37:AM-MOD
36	be	be	VB	_	37	auxpass	_
37	treated	treat	VBN	pb=treat.01	30	rcmod	_
38	with	with	IN	_	37	prep	37:A2=PRD
39	an	an	DT	_	47	det	_
40	inhaled	inhaled	JJ	p2=VBN	47	amod	_
41	,	,	,	_	47	punct	_
42	short	short	JJ	p2=RB	44	hmod	_
43	-	-	HYPH	_	44	hyph	_
44	acting	act	VBG	p2=NN	47	amod	_
45	beta2	beta0	NN	p2=''	47	hmod	_
46	-	-	HYPH	_	47	hyph	_
47	agonist	agonist	NN	p2=JJ	38	pobj	_
48	.	.	.	_	6	punct	_

1	As	as	IN	p2=RB	10	prep	10:AM-MNR
2	with	with	IN	_	1	prep	_
3	other	other	JJ	_	5	amod	_
4	inhaled	inhaled	JJ	p2=VBN	5	amod	_
5	medicines	medicine	NNS	_	2	pobj	_
6	,	,	,	_	10	punct	_
7	Incruse	incruse	NNP	p2=NNPS	8	nn	_
8	Ellipta	ellipta	NNP	_	10	nsubj	10:A0=PAG
9	can	can	MD	_	10	aux	10:AM-MOD
10	produce	produce	VB	pb=produce.01	0	root	_
11	paradoxical	paradoxical	JJ	p2=NNP	12	amod	_
12	bronchospasm	bronchospasm	NN	p2=NNS	10	dobj	10:A1;16:A1=PPT
13	,	,	,	_	12	punct	_
14	which	which	WDT	_	16	nsubj	16:R-A1
15	may	may	MD	_	16	aux	16:AM-MOD
16	be	be	VB	pb=be.01	12	rcmod	_
17	life	life	NN	_	19	hmod	_
18	-	-	HYPH	_	19	hyph	_
19	threatening	threatening	NN	p2=VBG	16	attr	16:A2=PRD
20	.	.	.	_	10	punct	_

1	Incruse	incruse	VB	p2=IN	2	nn	_
2	Ellipta	ellipta	NNP	_	5	nsubjpass	5:A1=PPT
3	should	should	MD	_	5	aux	5:AM-MOD
4	be	be	VB	_	5	auxpass	_
5	used	use	VBN	pb=use.01	0	root	_
6	with	with	IN	_	5	prep	5:AM-MNR
7	caution	caution	NN	_	6	pobj	_
8	in	in	IN	_	7	prep	_
9	patients	patient	NNS	_	8	pobj	_
10	with	with	IN	_	9	prep	_
11	narrow	narrow	JJ	_	13	hmod	_
12	-	-	HYPH	_	13	hyph	_
13	angle	angle	NN	_	14	nn	_
14	glaucoma	glaucoma	NN	_	10	pobj	_
15	.	.	.	_	5	punct	_

1	Instruct	instruct	VB	p2=JJ|pb=instruct.01	0	root	_
2	patients	patient	NNS	_	1	dobj	4:A0=PAG;1:A1=GOL
3	to	to	TO	_	4	aux	_
4	contact	contact	VB	pb=contact.01	1	xcomp	1:A2=PPT
5	a	a	DT	_	6	det	_
6	physician	physician	NN	_	4	dobj	4:A1=PPT
7	immediately	immediately	RB	_	4	advmod	4:AM-TMP
8	should	should	MD	_	18	aux	18:AM-MOD
9	any	any	DT	_	10	det	_
10	signs	sign	NNS	_	18	nsubj	18:A1=PPT
11	or	or	CC	_	10	cc	_
12	symptoms	symptom	NNS	_	10	conj	_
13	of	of	IN	_	10	prep	_
14	narrow	narrow	JJ	_	16	hmod	_
15	-	-	HYPH	_	16	hyph	_
16	angle	angle	NN	_	17	nn	_
17	glaucoma	glaucoma	NN	p2=NNS	13	pobj	_
18	occur	occur	VBP	p2=NN|pb=occur.01	1	advcl	_
19	.	.	.	_	1	punct	_

1	Incruse	incruse	VB	p2=IN	2	nn	_
2	Ellipta	ellipta	NNP	_	5	nsubjpass	5:A1=PPT
3	should	should	MD	_	5	aux	5:AM-MOD
4	be	be	VB	_	5	auxpass	_
5	used	use	VBN	pb=use.01	0	root	_
6	with	with	IN	_	5	prep	5:AM-MNR
7	caution	caution	NN	_	6	pobj	_
8	in	in	IN	_	7	prep	_
9	patients	patient	NNS	_	8	pobj	_
10	with	with	IN	_	9	prep	_
11	urinary	urinary	JJ	p2=NN	12	amod	_
12	retention	retention	NN	_	10	pobj	_
13	,	,	,	_	12	punct	_
14	especially	especially	RB	_	15	advmod	_
15	in	in	IN	_	12	prep	_
16	patients	patient	NNS	_	15	pobj	_
17	with	with	IN	_	16	prep	_
18	prostatic	prostatic	JJ	_	19	amod	_
19	hyperplasia	hyperplasia	NN	p2=NNS	17	pobj	_
20	or	or	CC	_	19	cc	_
21	bladder	bladder	NN	_	22	nn	_
22	neck	neck	NN	_	23	nn	_
23	obstruction	obstruction	NN	_	19	conj	_
24	.	.	.	_	5	punct	_

1	 	 	POS	p2=``	2	nn	_
2	Instruct	instruct	NNP	p2=JJ	3	nn	_
3	patients	patient	NNS	p2=VBZ	5	nsubj	5:A0=PAG
4	to	to	TO	p2=IN	5	aux	_
5	contact	contact	VB	pb=contact.01	0	root	_
6	a	a	DT	_	7	det	_
7	physician	physician	NN	_	5	dobj	5:A1=PPT
8	immediately	immediately	RB	_	17	advmod	_
9	should	should	MD	_	17	aux	17:AM-MOD
10	any	any	DT	_	11	det	_
11	signs	sign	NNS	_	17	nsubj	17:A1=PPT
12	or	or	CC	_	11	cc	_
13	symptoms	symptom	NNS	_	11	conj	_
14	of	of	IN	_	11	prep	_
15	urinary	urinary	JJ	p2=DT	16	amod	_
16	retention	retention	NN	_	14	pobj	_
17	occur	occur	VBP	p2=NN|pb=occur.01	5	advcl	5:AM-TMP
18	.	.	.	_	5	punct	_

1	The	the	DT	_	5	det	_
2	most	most	RBS	_	3	advmod	_
3	common	common	JJ	_	5	amod	_
4	adverse	adverse	JJ	_	5	amod	_
5	reactions	reaction	NNS	_	0	root	_
6	(	(	-LRB-	_	5	punct	_
7	incidence	incidence	NN	p2=VB	8	nsubj	_
8	>	>	XX	p2=IN	10	dep	_
9	/	/	SYM	p2=NFP	10	punct	_
10	=2	=0	CD	p2=NN	5	appos	_
11	%	%	NN	_	10	quantmod	_
12	and	and	CC	_	10	cc	_
13	more	more	RBR	p2=JJR	14	advmod	_
14	common	common	JJ	_	10	conj	_
15	than	than	IN	_	14	prep	_
16	placebo	placebo	NN	_	15	pobj	_
17	)	)	-RRB-	_	7	punct	_
18	with	with	IN	_	7	prep	_
19	Incruse	incruse	NNP	p2=NN	20	nn	_
20	Ellipta	ellipta	NNP	_	18	pobj	_
21	(	(	-LRB-	_	20	punct	_
22	and	and	CC	_	20	cc	_
23	placebo	placebo	NN	_	20	conj	_
24	)	)	-RRB-	_	26	punct	_
25	were	be	VBD	_	26	auxpass	_
26	nasopharyngitis	nasopharyngitis	FW	p2=NNS	0	root	_
27	,	,	,	_	26	punct	_
28	8	0	CD	_	29	num	_
29	%	%	NN	_	26	npadvmod	_
30	(	(	-LRB-	_	29	punct	_
31	7	0	CD	_	32	num	_
32	%	%	NN	_	29	appos	_
33	)	)	-RRB-	_	29	punct	_
34	;	;	,	p2=:	29	punct	_
35	upper	upper	JJ	_	38	amod	_
36	respiratory	respiratory	JJ	_	37	amod	_
37	tract	tract	NN	_	38	nn	_
38	infection	infection	NN	_	26	conj	_
39	,	,	,	_	38	punct	_
40	5	0	CD	_	41	num	_
41	%	%	NN	_	5	appos	_
42	(	(	-LRB-	_	41	punct	_
43	4	0	CD	_	44	num	_
44	%	%	NN	_	41	appos	_
45	)	)	-RRB-	_	41	punct	_
46	;	;	:	p2=,	41	punct	_
47	cough	cough	NN	p2=FW	41	appos	_
48	,	,	,	_	47	punct	_
49	3	0	CD	_	50	num	_
50	%	%	NN	_	5	appos	_
51	(	(	-LRB-	_	50	punct	_
52	2	0	CD	_	53	num	_
53	%	%	NN	_	50	appos	_
54	)	)	-RRB-	_	50	punct	_
55	;	;	:	p2=,	50	punct	_
56	and	and	CC	_	50	cc	_
57	arthralgia	arthralgia	NNP	p2=NN	50	conj	_
58	,	,	,	_	57	punct	_
59	2	0	CD	_	60	num	_
60	%	%	NN	_	5	appos	_
61	(	(	-LRB-	_	60	punct	_
62	1	0	CD	_	63	num	_
63	%	%	NN	_	60	appos	_
64	)	)	-RRB-	_	60	punct	_
65	.	.	.	_	26	punct	_

1	Other	other	JJ	_	3	amod	_
2	adverse	adverse	JJ	_	3	amod	_
3	reactions	reaction	NNS	_	7	nsubj	7:A0=PPT
4	with	with	IN	_	3	prep	_
5	Incruse	incruse	NNP	p2=NNPS	6	nn	_
6	Ellipta	ellipta	NNP	_	4	pobj	_
7	observed	observe	VBD	p2=VBN|pb=observe.01	0	root	_
8	with	with	IN	_	7	prep	7:AM-MNR
9	an	an	DT	_	10	det	_
10	incidence	incidence	NN	_	8	pobj	_
11	less	less	JJR	_	13	amod	_
12	than	than	IN	_	13	quantmod	_
13	1	0	CD	_	14	num	_
14	%	%	NN	_	20	nsubj	20:A2=GOL
15	but	but	CC	_	7	cc	_
16	more	more	RBR	p2=JJR	17	advmod	_
17	common	common	JJ	_	14	amod	_
18	than	than	IN	_	17	prep	_
19	placebo	placebo	NN	_	18	pobj	_
20	included	include	VBN	p2=VBD|pb=include.01	7	conj	_
21	atrial	atrial	JJ	p2=NN	22	amod	_
22	fibrillation	fibrillation	NN	_	20	dobj	20:A1=PPT
23	.	.	.	_	20	punct	_

1	Avoid	avoid	VB	pb=avoid.01	0	root	_
2	co-administration	co-administration	NN	_	1	dobj	1:A1=PPT
3	of	of	IN	_	2	prep	_
4	Incruse	incruse	NNP	p2=NN	5	nn	_
5	Ellipta	ellipta	NNP	_	3	pobj	_
6	with	with	IN	_	1	prep	1:AM-MNR
7	other	other	JJ	_	11	amod	_
8	anticholinergic	anticholinergic	JJ	p2=NN	10	hmod	_
9	-	-	HYPH	_	10	hyph	_
10	containing	contain	VBG	_	11	amod	_
11	drugs	drug	NNS	_	6	pobj	_
12	as	as	IN	_	15	mark	_
13	this	this	DT	_	15	nsubj	15:A0=PAG
14	may	may	MD	_	15	aux	15:AM-MOD
15	lead	lead	VB	pb=lead.03	1	advcl	1:AM-CAU
16	to	to	IN	_	15	prep	15:A2=PRD
17	an	an	DT	_	18	det	_
18	increase	increase	NN	_	16	pobj	_
19	in	in	IN	_	18	prep	_
20	anticholinergic	anticholinergic	JJ	_	22	amod	_
21	adverse	adverse	JJ	_	22	amod	_
22	effects	effect	NNS	_	19	pobj	_
23	such	such	JJ	_	24	amod	_
24	as	as	IN	_	22	prep	_
25	worsening	worsen	VBG	p2=NN	24	pobj	_
26	of	of	IN	_	25	prep	_
27	narrow	narrow	JJ	_	29	hmod	_
28	-	-	HYPH	_	29	hyph	_
29	angle	angle	NN	_	30	nn	_
30	glaucoma	glaucoma	NN	_	26	pobj	_
31	,	,	,	_	25	punct	_
32	and	and	CC	_	25	cc	_
33	worsening	worsen	VBG	p2=NN|pb=worsen.01	25	conj	_
34	of	of	IN	_	33	prep	33:A1=PPT
35	urinary	urinary	JJ	_	36	amod	_
36	retention	retention	NN	_	34	pobj	_
37	.	.	.	_	1	punct	_

1	INCRUSE™	incruse™	NNP	p2=NNS	8	nsubj	8:A1=PPT
2	,	,	,	_	1	punct	_
3	ELLIPTA®	ellipta®	NNP	_	1	conj	_
4	,	,	,	_	3	punct	_
5	ADVAIR®	advair®	NNP	_	3	conj	_
6	and	and	CC	_	5	cc	_
7	DISKUS®	diskus®	NNP	_	5	conj	_
8	are	be	VBP	pb=be.01	0	root	_
9	trademarks	trademark	NNS	_	8	attr	8:A2=PRD
10	of	of	IN	_	9	prep	_
11	the	the	DT	_	13	det	_
12	GlaxoSmithKline	glaxosmithkline	NNP	p2=JJ	13	nn	_
13	group	group	NN	_	10	pobj	_
14	of	of	IN	_	13	prep	_
15	companies	company	NNS	_	14	pobj	_
16	.	.	.	_	8	punct	_

1	GSK	gsk	NNP	p2=NN	3	hmod	_
2	-	-	HYPH	p2=:	3	hyph	_
3	one	#crd#	CD	p2=NNP	16	nsubjpass	16:A1=PPT
4	of	of	IN	_	3	prep	_
5	the	the	DT	_	6	det	_
6	world	world	NN	_	13	poss	_
7	's	's	POS	_	6	possessive	_
8	leading	lead	VBG	p2=NN|pb=lead.01	13	amod	_
9	research-based	research-based	JJ	p2=VBD	13	amod	_
10	pharmaceutical	pharmaceutical	NN	p2=JJ	13	nn	_
11	and	and	CC	_	10	cc	_
12	healthcare	healthcare	NN	_	10	conj	_
13	companies	company	NNS	_	4	pobj	8:A0=PAG
14	-	-	,	p2=:	3	punct	_
15	is	be	VBZ	_	16	auxpass	_
16	committed	commit	VBN	p2=JJ|pb=commit.01	0	root	_
17	to	to	IN	_	16	prep	16:A2=GOL
18	improving	improve	VBG	pb=improve.01	17	pcomp	_
19	the	the	DT	_	20	det	_
20	quality	quality	NN	_	18	dobj	18:A1=PPT
21	of	of	IN	_	20	prep	_
22	human	human	JJ	p2=NN	23	amod	_
23	life	life	NN	_	21	pobj	_
24	by	by	IN	_	18	prep	18:AM-MNR
25	enabling	enable	VBG	pb=enable.01	24	pcomp	_
26	people	people	NNS	_	25	dobj	28:A0=PAG;31:A0=PPT;25:A2
27	to	to	TO	_	28	aux	_
28	do	do	VB	pb=do.02	25	xcomp	25:A1=PPT
29	more	more	JJR	_	28	dobj	28:A1=PPT
30	,	,	,	_	28	punct	_
31	feel	feel	VB	pb=feel.01	28	dep	_
32	better	good	JJR	p2=RBR	31	acomp	31:A1=PPT
33	and	and	CC	_	32	cc	_
34	live	live	RB	p2=VB	32	conj	_
35	longer	long	RBR	p2=JJR	34	advmod	_
36	.	.	.	_	16	punct	_

1	 	 	``	p2=NFP	6	punct	_
2	For	for	IN	_	6	prep	6:AM-DIS
3	further	far	JJ	p2=RB	4	amod	_
4	information	information	NN	_	2	pobj	_
5	please	please	UH	_	6	intj	6:AM-DIS
6	visit	visit	VB	p2=NN|pb=visit.01	0	root	_
7	www.gsk.com	#url#	ADD	_	6	dobj	6:A1=COM
8	.	.	.	_	6	punct	_

1	GSK	gsk	NNP	p2=NN	2	nsubj	2:A0=PAG
2	cautions	caution	VBZ	pb=caution.01	0	root	_
3	investors	investor	NNS	_	2	dobj	2:A2=GOL
4	that	that	IN	p2=WDT	23	complm	_
5	any	any	DT	_	9	det	_
6	forward	forward	RB	_	8	hmod	_
7	-	-	HYPH	_	8	hyph	_
8	looking	look	VBG	_	9	amod	_
9	statements	statement	NNS	_	23	nsubj	12:A1=PRD;23:A1=PPT
10	or	or	CC	_	9	cc	_
11	projections	projection	NNS	_	9	conj	_
12	made	make	VBN	pb=make.01	9	partmod	_
13	by	by	IN	_	12	agent	12:A0=PAG
14	GSK	gsk	NNP	_	13	pobj	_
15	,	,	,	_	9	punct	_
16	including	include	VBG	_	9	prep	_
17	those	those	DT	_	16	pobj	18:A1=PRD
18	made	make	VBN	pb=make.01	17	partmod	_
19	in	in	IN	_	18	prep	18:AM-LOC
20	this	this	DT	_	21	det	_
21	announcement	announcement	NN	_	19	pobj	_
22	,	,	,	_	9	punct	_
23	are	be	VBP	pb=be.01	2	ccomp	2:A1=PPT
24	subject	subject	JJ	_	23	acomp	23:A2=PRD
25	to	to	IN	_	24	prep	_
26	risks	risk	NNS	_	25	pobj	31:A0=CAU
27	and	and	CC	_	26	cc	_
28	uncertainties	uncertainty	NNS	_	26	conj	_
29	that	that	WDT	_	31	nsubj	31:R-A0
30	may	may	MD	_	31	aux	31:AM-MOD
31	cause	cause	VB	pb=cause.01	26	rcmod	_
32	actual	actual	JJ	_	33	amod	_
33	results	result	NNS	_	35	nsubj	35:A1=PPT
34	to	to	TO	_	35	aux	_
35	differ	differ	VB	pb=differ.02	31	ccomp	31:A1=PPT
36	materially	materially	RB	_	35	advmod	35:AM-MNR
37	from	from	IN	_	35	prep	35:C-A1
38	those	those	DT	_	37	pobj	39:A1=PPT
39	projected	project	VBN	pb=project.02	38	partmod	_
40	.	.	.	_	2	punct	_

1	Such	such	JJ	_	2	amod	_
2	factors	factor	NNS	_	3	nsubj	3:A2=GOL
3	include	include	VBP	pb=include.01	0	root	_
4	,	,	,	_	3	punct	_
5	but	but	CC	_	3	cc	_
6	are	be	VBP	_	8	auxpass	_
7	not	not	RB	_	8	neg	8:AM-NEG
8	limited	limit	VBN	p2=JJ|pb=limit.01	3	conj	_
9	to	to	IN	_	8	prep	8:A2=GOL
10	,	,	,	_	3	punct	_
11	those	those	DT	_	9	pobj	12:A1=PPT
12	described	describe	VBN	pb=describe.01	11	partmod	_
13	under	under	IN	_	12	prep	12:AM-LOC
14	Item	item	NNP	p2=``	15	nn	_
15	3.D	3.d	NNP	p2=LS	18	poss	_
16	'	'	POS	p2=''	15	possessive	_
17	Risk	risk	NN	p2=NNP	18	nn	_
18	factors	factor	NNS	_	13	pobj	_
19	'	'	''	_	18	punct	_
20	in	in	IN	_	18	prep	_
21	the	the	DT	_	22	det	_
22	company	company	NN	_	25	poss	_
23	's	's	POS	_	22	possessive	_
24	Annual	annual	NNP	_	25	nn	_
25	Report	report	NNP	_	20	pobj	_
26	on	on	IN	_	25	prep	_
27	Form	form	NNP	p2=NN	26	pobj	_
28	20	0	CD	p2=NNP	27	num	_
29	-	-	:	p2=HYPH	30	punct	_
30	F	f	NNP	p2=CD	27	appos	_
31	for	for	IN	_	30	prep	_
32	2013	0	CD	_	31	pobj	_
33	.	.	.	_	3	punct	_

